Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SP 16

Next Previous
Drug Profile

SP 16

Alternative Names: Serpin Peptide 16; SP-16

Latest Information Update: 06 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Serpin Pharma
  • Developer Serpin Pharma; Virginia Commonwealth University
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antihyperglycaemics; Cardiovascular therapies; Oligopeptides; Peptides; Serpins; Skin disorder therapies
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Inflammation; Myocardial infarction; SARS-CoV-2 acute respiratory disease
  • Preclinical Acute kidney injury; Atopic dermatitis; Chronic inflammatory demyelinating polyradiculoneuropathy; Eosinophilic oesophagitis; Neuropathic pain
  • Research Alopecia areata; Pemphigus vulgaris
  • No development reported Diabetes mellitus; Myocardial reperfusion injury

Most Recent Events

  • 02 Mar 2026 Serpin Pharma plans a phase II EASE AKI trial for Acute kidney injury (Prevention) in Germany (SC, Injection) (CTIS2025-522491-89-00)
  • 16 Feb 2026 Serpin Pharma announces approval to initiate EASE AKI phase II Clinical Trial for Acute kidney injury in Germany
  • 06 Nov 2025 Preclinical trials in Neuropathic pain in USA (IV) before November 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top